CXCR4 and neoplasm: The CXCR4-A oncolytic virotherapy-generated immunogenic tumor cell “cargo” for DC loading has the potential to be further enhanced by combination with ICD-inducing chemotherapeutic agents, such as doxorubicin, to promote improved antigen presentation to T cells54 because of a synergistic interaction between OVV and doxorubicin.8